

Peer Review File

Article information: <https://dx.doi.org/10.21037/hbsn-23-395>

Reviewer A:

Comment 1: The work completed by your team is very rare and contains clinical significance. We look forward to the follow-up of the patient, so as to provide clinical experience support for surgical resection plans for patients with the same disease.

Reply 1: Thank you for your comment! At the time of the initial submission of this article, the patient had a follow-up time of 4 months postoperatively and was undergoing adjuvant chemotherapy. Currently, it has been 6 months postoperatively, and the patient has completed two cycles of chemotherapy and underwent a follow-up enhanced CT scan. We were pleasantly surprised to find that the patient's portal vein was patent, no tumor thrombus was observed, and there was no evidence of tumor recurrence on imaging. This follow-up information has been added to the manuscript. We have included the enhanced CT images of the patient at 6 months postoperatively in the manuscript.

Changes in the text: Page 2, Line 59-63.

Comment 2: 2. in row 73: (PDAC) c should drop the "c".

Reply 2: Thank you for your comment! We have removed the unnecessary character "c".

Changes in the text: Page 2, Line 73.

Reviewer B:

Comment 3: I want to congratulate the authors for their successful medical and surgical treatment of this patient. The chemotherapy response is impressive, and the surgery was beautifully done. The manuscript is well-written, and the figures and images were adequate. I have one request for the readers who might have the same question: Can the author comment on the neoadjuvant treatment response of ACC in this patient and provide one paragraph describing the usual treatment response of ACC to neoadjuvant therapy?

Reply 3:

Thank you for your comment! Due to space limitations, this article mainly focuses on surgical techniques, such as indications and operative techniques for portal vein resection and thrombectomy. We did not extensively discuss neoadjuvant chemotherapy for ACC. The significant neoadjuvant effect in this patient was mainly due to the BRCA2 gene mutation, which makes platinum-based chemotherapy regimens more effective. We have added a paragraph to discuss this issue and reviewed relevant literature.

Changes in the text: Page 2, Line 69-77.